Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
Phase 2
Completed
- Conditions
- Perennial Allergy to House Dust Mite and/or Cat
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2009-04-27
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 64
- Registration Number
- NCT00575003
- Locations
- 🇪🇪
Tartu University Clinic, Lungs Clinic, Tartu, Estonia
🇱🇻The centre of the investigation in treatment of allergic disease, Riga, Latvia
🇱🇹Kaunas Medical University Hospital, Department of Pulmonology and Immunology, Kaunas, Lithuania
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
Phase 2
Completed
- Conditions
- Perennial Allergic RhinoconjunctivitisHouse Dust Mite Allergy
- Interventions
- Drug: CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)Drug: House dust mite allergen extract in combination with CYT003-QbG10-placeboDrug: CYT003-AllQbG10 in combination with house dust mite allergen extract placeboDrug: CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 40
- Registration Number
- NCT00574704
Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb
Phase 1
Completed
- Conditions
- Essential Hypertension
- Interventions
- Biological: CYT006-AngQb
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2012-08-21
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 88
- Registration Number
- NCT00500786
Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers
Phase 2
Completed
- Conditions
- Smokers
- Interventions
- Biological: CYT002-NicQb
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 341
- Registration Number
- NCT00369616
- Locations
- 🇨🇭
University Hospital Lausanne (CHUV), Lausanne, Vaud, Switzerland
🇨🇭Lungenzentrum Hirslandenklinik Zuerich, Zuerich, Switzerland
🇨🇭Kantonsspital St. Gallen, St. Gallen, Switzerland
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients
Phase 2
Completed
- Conditions
- Malignant Melanoma
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2006-09-19
- Lead Sponsor
- Cytos Biotechnology AG
- Registration Number
- NCT00306553
- Locations
- 🇨🇭
Dept. of Dermatology, USZ, Zuerich, Switzerland
🇨🇭Dept. of Oncology, USZ, Zuerich, Switzerland
Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients
Phase 1
Completed
- Conditions
- Malignant Melanoma
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2007-09-20
- Lead Sponsor
- Cytos Biotechnology AG
- Registration Number
- NCT00306566
- Locations
- 🇨🇭
Centre Pluridisciplinaire d'Oncologie & LICR, CHUV, Lausanne, Vaude, Switzerland
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients
Phase 1
Completed
- Conditions
- Melanoma
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2007-09-20
- Lead Sponsor
- Cytos Biotechnology AG
- Registration Number
- NCT00306514
- Locations
- 🇩🇪
Dept. of Dermatology, Venerology and Allergy, Berlin, Germany
Safety and Efficacy of an Allergen Vaccine in Grass-Pollen Allergy
Phase 1
Completed
- Conditions
- Hypersensitivity
- First Posted Date
- 2006-02-20
- Last Posted Date
- 2007-09-20
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 36
- Registration Number
- NCT00293904
- Locations
- 🇨🇭
University Hospital of Zürich, Zürich, Switzerland
© Copyright 2025. All Rights Reserved by MedPath